首页> 外国专利> BLADDER INSULATION COMPOSITION CONTAINING CHONDROITIN SULPHATE (20 MG/ML), HYALURONIC ACID (16 MG/ML) AND PHOSPHATE BUFFER (pH 6.1-7.9), WITH INCREASED STORAGE STABILITY FOR CYSTITIS TREATMENT

BLADDER INSULATION COMPOSITION CONTAINING CHONDROITIN SULPHATE (20 MG/ML), HYALURONIC ACID (16 MG/ML) AND PHOSPHATE BUFFER (pH 6.1-7.9), WITH INCREASED STORAGE STABILITY FOR CYSTITIS TREATMENT

机译:含有软骨素(20mg / ml),透明质酸(16mg / ml)和磷酸盐缓冲液(pH6.1-7.9)的膀胱绝缘组合物,具有增加的膀胱炎治疗稳定性

摘要

FIELD: pharmaceutical industry.;SUBSTANCE: invention relates to pharmaceutical industry, in particular to the use of the composition for the prophylactic and/or therapeutic treatment of cystitis. Use of a composition for the prophylactic and/or therapeutic treatment of cystitis, where the composition contains in an effective amount a physiologically compatible salt of chondroitin sulfate in the form of an alkali metal salt at a concentration of 20±2 mg/ml as component (a), where the physiologically compatible salt of chondroitin sulfate has a weight average molecular weight Mw ranging from 10 to 200 kDa, a physiologically compatible hyaluronic acid salt (hyaluronate) in the form of an alkali metal salt at a concentration of 16±1.6 mg/ml as component (b), where the physiologically compatible hyaluronic acid salt has a weight average molecular weight Mw in the range from 10 to 500 kDa, a dihydrogen phosphate/monohydrogen phosphate buffer system as component (c), where the composition contains a dihydrogen phosphate/monohydrogen phosphate buffer system at a total concentration of a dihydrogen phosphate/monohydrogen phosphate buffer system of 1.75±1.65 mg/ml, and where the composition contains a dihydrogen phosphate/monohydrogen phosphate buffer system in the ratio of the mass of dihydrogen phosphate and monohydrogen phosphate in the range from 2:1 to 1:100, at least one physiologically compatible electrolyte as component (d), where the composition contains an electrolyte at a concentration of 8±6 mg/ml, and where the electrolyte is in the form of an alkali metal salt, wherein the composition has a pH in the range of 6.1 to 7.9.;EFFECT: invention has high storage stability and is highly effective in treating cystitis such as interstitial cystitis.;2 cl, 19 tbl, 1 ex
机译:领域:制药业。;物质:发明涉及制药工业,特别是使用组合物用于预防和/或治疗膀胱炎的治疗方法。使用组合物用于胱型和/或治疗膀胱炎的治疗方法,其中组合物含有有效量的硫酸盐的生理相容盐,浓度为20±2mg / ml作为组分的浓度为20±2mg / ml (a),其中硫酸软骨素的生理相容盐的重均分子量Mw为10-200kDa,浓度为16±1.6的碱金属盐形式的生理学上相容的透明质酸盐(透明质酸)。 Mg / ml作为组分(b),其中生理学相容的透明质酸盐的重均分子量Mw为10-500kda,磷酸二氢/一磷酸盐缓冲系统作为组分(c),其中组合物含有磷酸二氢/一磷酸二氢盐缓冲体系,其磷酸二氢磷酸二氢磷酸二氢盐缓冲体系的总浓度为1.75±1.65mg / ml,其中复合材料离子含有二氢磷酸二氢磷酸二氢盐缓冲体系,其磷酸二氢和一元磷酸盐的比例为2:1至1:100,至少一种生理学上相容的电解质作为组分(d),其中组合物含有浓度为8±6mg / ml的电解质,其中电解质是碱金属盐的形式,其中组合物的pH值为6.1至7.9。;效果:发明具有高存储稳定性和在治疗间质膀胱炎等膀胱炎方面非常有效。; 2 cl,19 tbl,1前

著录项

  • 公开/公告号RU0002745869C1

    专利类型

  • 公开/公告日2021-04-02

    原文格式PDF

  • 申请/专利权人

    申请/专利号RU2019140847

  • 发明设计人 MEIER ANDREAS (DE);

    申请日2018-05-02

  • 分类号A61K31/728;A61K31/737;A61K9/08;A61P13/10;A61P29;

  • 国家 RU

  • 入库时间 2022-08-24 18:06:49

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号